Trial Profile
A Single Dose, Open Label, Randomized, Two-period Cross Over Study in Healthy Male Subjects to Assess the Absolute Bioavailability of YM178 OCAS-M Formulation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jul 2013
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Mirabegron (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- 04 Sep 2012 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
- 28 Nov 2011 New trial record